LungLife AI Inc (LLAI) - Total Assets
Based on the latest financial reports, LungLife AI Inc (LLAI) holds total assets worth GBX9.06 Million GBX (≈ $1.10K USD) as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See LLAI net asset quality index to measure how much of total assets are equity-financed.
LungLife AI Inc - Total Assets Trend (2018–2023)
This chart illustrates how LungLife AI Inc's total assets have evolved over time, based on quarterly financial data. Check LLAI goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
LungLife AI Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
LungLife AI Inc's total assets of GBX9.06 Million consist of 34.7% current assets and 65.3% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 28.6% |
| Accounts Receivable | GBX175.00K | 1.8% |
| Inventory | GBX-175.00K | -1.8% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX5.82 Million | 61.1% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2018–2023)
This chart illustrates how LungLife AI Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see LungLife AI Inc (LLAI) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LungLife AI Inc's current assets represent 34.7% of total assets in 2023, a decrease from 50.4% in 2018.
- Cash Position: Cash and equivalents constituted 28.6% of total assets in 2023, down from 30.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 61.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 61.1% of total assets.
LungLife AI Inc Competitors by Total Assets
Key competitors of LungLife AI Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.52 Billion |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
|
SCOPE FLUIDICS SA ZY-10
F:S84
|
Germany | €195.94 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Leveljump Healthcare Corp
V:JUMP
|
Canada | CA$21.84 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
LungLife AI Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.83 | 4.08 | 0.15 |
| Quick Ratio | 2.83 | 4.08 | 0.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX1.92 Million | GBX4.41 Million | GBX-3.86 Million |
LungLife AI Inc - Advanced Valuation Insights
This section examines the relationship between LungLife AI Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.22 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -36.6% |
| Total Assets | GBX9.52 Million |
| Market Capitalization | $15.48K USD |
Valuation Analysis
Below Book Valuation: The market values LungLife AI Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: LungLife AI Inc's assets decreased by 36.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LungLife AI Inc (2018–2023)
The table below shows the annual total assets of LungLife AI Inc from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | GBX9.52 Million ≈ $1.16K |
-36.60% |
| 2022-12-31 | GBX15.02 Million ≈ $1.83K |
-31.62% |
| 2021-12-31 | GBX21.97 Million ≈ $2.67K |
+2.07% |
| 2020-12-31 | GBX21.52 Million ≈ $2.62K |
+1142.03% |
| 2019-12-31 | GBX1.73 Million ≈ $210.82 |
+140.20% |
| 2018-12-31 | GBX721.36K ≈ $87.77 |
-- |
About LungLife AI Inc
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, I… Read more